Sugi Predict

Sugi Predict / Compounds / SCHEMBL5019943

SCHEMBL5019943

SCHEMBL5019943

CC(=O)O[C@H]1C[C@@H](Cc2c[nH]c3cc(F)ccc23)N(C(=O)OCc2ccccc2)C1

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 1/20 0.41
▸ DRD4 P21917 2/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ ACHE P22303 1/20 0.39
▸ HTR6 P50406 2/20 0.38
▸ POLB P06746 1/20 0.36
▸ CTSK P43235 2/20 0.36
▸ CTSB P07858 1/20 0.36
▸ CTSS P25774 1/20 0.36
▸ GPR84 Q9NQS5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL946384 1.00 TGM2 (0.41) TGM2DRD4SIGMAR1ACHEHTR6
SCHEMBL12944880 1.00 TGM2 (0.41) TGM2DRD4SIGMAR1ACHEHTR6
SCHEMBL29993724 1.00 TGM2 (0.41) TGM2DRD4SIGMAR1ACHEHTR6
SCHEMBL5019960 0.92 TGM2 (0.40) TGM2DRD4SIGMAR1ACHEHTR6
SCHEMBL820565 0.89 ERAP2 (0.43) HTR6GPR84
SCHEMBL16791288 0.89 TGM2 (0.42) TGM2DRD4SIGMAR1ACHEHTR6
SCHEMBL19540487 0.88 TGM2 (0.43) TGM2DRD4SIGMAR1ACHEHTR6
SCHEMBL12944882 0.88 POLB (0.44) TGM2DRD4SIGMAR1ACHEHTR6
SCHEMBL29993238 0.88 POLB (0.44) TGM2DRD4SIGMAR1ACHEHTR6
SCHEMBL943113 0.88 POLB (0.44) TGM2DRD4SIGMAR1ACHEHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149500-A1 SMAC MIMETIC MEDIVIR AB (SE) 2023-05-18 — — US disclosed
US-11351221-B2 SMAC mimetic MEDIVIR AB (SE) 2022-06-07 — — US disclosed
US-20200282002-A1 SMAC Mimetic MEDIVIR AB (SE) 2020-09-10 — — US disclosed
US-10596220-B2 SMAC mimetic MEDIVIR AB (SE) 2020-03-24 — — US disclosed
US-20190255139-A1 SMAC Mimetic MEDIVIR AB (SE) 2019-08-22 — — US disclosed
WO-2019154053-A1 IAP INHIBITOR AND USE OF SAME IN MEDICINE 广东东阳光药业有限公司 2019-08-15 — — WO disclosed
US-10314881-B2 SMAC mimetic MEDIVIR AB (SE) 2019-06-11 — — US disclosed
US-10034912-B2 SMAC Mimetic TetraLogic Birinapant UK Ltd. (GB) 2018-07-31 — — US disclosed
US-10034912-B2 SMAC Mimetic TetraLogic Birinapant UK Ltd. (GB) 2018-07-31 — — US disclosed
US-20170182116-A1 SMAC Mimetic MEDIVIR AB (SE) 2017-06-29 — — US disclosed
WO-2013049350-A1 SMAC MIMETIC (BIRINAPANT) FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES (CANCER) TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2013-04-04 — — WO disclosed
US-20130012564-A1 SMAC Mimetic TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-01-10 — — US disclosed
US-20130012564-A1 SMAC Mimetic TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-01-10 — — US disclosed
US-8283372-B2 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic TETRALOGIC PHARMACEUTICALS CORP. (US) 2012-10-09 — — US disclosed
US-8283372-B2 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic TETRALOGIC PHARMACEUTICALS CORP. (US) 2012-10-09 — — US disclosed
US-20120115922-A1 SMAC MIMETEC MEDIVIR AB (SE) 2012-05-10 — — US disclosed
US-20120115922-A1 SMAC MIMETEC MEDIVIR AB (SE) 2012-05-10 — — US disclosed
US-20110003877-A1 SMAC Mimetic TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2011-01-06 — — US disclosed
US-20110003877-A1 SMAC Mimetic TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2011-01-06 — — US disclosed
WO-2011002684-A1 SMAC MIMETIC TETRALOGIC PHARMACEUTICALS CORP. (US) 2011-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012564-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1917/4885
US-10596220-B2 SMAC mimetic SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1918/4885
US-20110003877-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1917/4885
US-10314881-B2 SMAC mimetic SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1917/4885
US-20170182116-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1918/4885
US-10034912-B2 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1917/4885
US-20120115922-A1 SMAC MIMETEC SMARCC1, SMARCC2, SMARCE1 TGM2 3340/4885DRD4 4877/4885SIGMAR1 2666/4885
US-20230149500-A1 SMAC MIMETIC SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1917/4885
US-11351221-B2 SMAC mimetic SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1918/4885
US-20200282002-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1918/4885
US-20190255139-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 TGM2 3272/4885DRD4 4882/4885SIGMAR1 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.